Last reviewed · How we verify
Esomeprazole (S14)
Esomeprazole (S14) is a Proton pump inhibitor (PPI) Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome. Also known as: Nexium.
Esomeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Esomeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Esomeprazole (S14) |
|---|---|
| Also known as | Nexium |
| Sponsor | National Taiwan University Hospital |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Esomeprazole is the active S-enantiomer of omeprazole that irreversibly binds to and inhibits the H+/K+-ATPase enzyme (proton pump) on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. It is used to treat acid-related disorders by maintaining elevated gastric pH.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Constipation
- Hypomagnesemia (with long-term use)
Key clinical trials
- Sequential Versus Quadruple Therapy in the Second-line Treatment (PHASE4)
- Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Esomeprazole (S14) CI brief — competitive landscape report
- Esomeprazole (S14) updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about Esomeprazole (S14)
What is Esomeprazole (S14)?
How does Esomeprazole (S14) work?
What is Esomeprazole (S14) used for?
Who makes Esomeprazole (S14)?
Is Esomeprazole (S14) also known as anything else?
What drug class is Esomeprazole (S14) in?
What development phase is Esomeprazole (S14) in?
What are the side effects of Esomeprazole (S14)?
What does Esomeprazole (S14) target?
Related
- Drug class: All Proton pump inhibitor (PPI) drugs
- Target: All drugs targeting H+/K+-ATPase (proton pump)
- Manufacturer: National Taiwan University Hospital — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastroesophageal reflux disease (GERD)
- Indication: Drugs for Peptic ulcer disease
- Indication: Drugs for Zollinger-Ellison syndrome
- Also known as: Nexium
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing